Cognition Therapeutics (CGTX) Net Shares Issued and Repurchased (2020 - 2025)

Cognition Therapeutics (CGTX) has reported Net Shares Issued and Repurchased for 6 consecutive years, with $643054.0 the latest figure, recorded in Q4 2025.

• On a quarterly basis, Net Shares Issued and Repurchased rose 159.82% year-over-year to $643054.0 in Q4 2025; TTM through Dec 2025 was $643054.0, a 159.82% increase from a year earlier, with the FY2025 full-year figure at $643054.0, up 159.82% from the prior year.
• Net Shares Issued and Repurchased was $643054.0 for Q4 2025 at Cognition Therapeutics, up from $247500.0 in the prior quarter.
• Over five years, Net Shares Issued and Repurchased peaked at $1.7 million in Q4 2021 and troughed at $11593.0 in Q2 2021.
• A 5-year average of $339456.3 and a median of $212450.0 in 2022 frame the typical range for Net Shares Issued and Repurchased.
• Across the five-year window, Net Shares Issued and Repurchased jumped 1747.02% in 2022 and plunged 74.01% in 2024, its largest moves.
• Over 5 years, Net Shares Issued and Repurchased stood at $1.7 million in 2021, then slumped by 69.1% to $524370.0 in 2022, then gained by 19.91% to $628769.0 in 2023, then plunged by 60.64% to $247500.0 in 2024, then soared by 159.82% to $643054.0 in 2025.
• The last three Net Shares Issued and Repurchased figures came in at $643054.0 (Q4 2025), $247500.0 (Q4 2024), and $42500.0 (Q2 2024), per Business Quant data.